257,100 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Bought by Ghisallo Capital Management LLC

Ghisallo Capital Management LLC bought a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 257,100 shares of the company's stock, valued at approximately $11,246,000. Revolution Medicines makes up about 0.7% of Ghisallo Capital Management LLC's investment portfolio, making the stock its 29th biggest position. Ghisallo Capital Management LLC owned 0.15% of Revolution Medicines as of its most recent SEC filing.

Several other large investors also recently modified their holdings of RVMD. Barclays PLC grew its holdings in shares of Revolution Medicines by 187.1% during the 3rd quarter. Barclays PLC now owns 294,664 shares of the company's stock worth $13,362,000 after purchasing an additional 192,021 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Revolution Medicines during the 3rd quarter worth $801,000. Lord Abbett & CO. LLC acquired a new stake in shares of Revolution Medicines during the 3rd quarter worth $83,082,000. Everence Capital Management Inc. acquired a new stake in shares of Revolution Medicines during the 4th quarter worth $203,000. Finally, Avanza Fonder AB acquired a new stake in shares of Revolution Medicines during the 4th quarter worth $173,000. 94.34% of the stock is owned by institutional investors and hedge funds.

Revolution Medicines Stock Up 7.0 %

NASDAQ RVMD traded up $2.70 on Monday, hitting $41.47. The company's stock had a trading volume of 2,872,304 shares, compared to its average volume of 1,437,485. Revolution Medicines, Inc. has a 1-year low of $29.17 and a 1-year high of $62.40. The company's 50-day moving average is $37.42 and its 200 day moving average is $43.95. The firm has a market cap of $7.71 billion, a PE ratio of -11.55 and a beta of 1.37.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.11). On average, equities analysts expect that Revolution Medicines, Inc. will post -3.49 EPS for the current year.

Insider Buying and Selling at Revolution Medicines

In other news, CFO Jack Anders sold 1,864 shares of the company's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total value of $72,770.56. Following the sale, the chief financial officer now directly owns 115,006 shares of the company's stock, valued at approximately $4,489,834.24. This represents a 1.59 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Margaret A. Horn sold 3,058 shares of the company's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $119,384.32. Following the completion of the sale, the chief operating officer now directly owns 153,533 shares in the company, valued at approximately $5,993,928.32. This represents a 1.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,660 shares of company stock worth $650,406. 8.00% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on RVMD. HC Wainwright increased their target price on Revolution Medicines from $72.00 to $73.00 and gave the stock a "buy" rating in a report on Monday, March 3rd. UBS Group raised their price objective on Revolution Medicines from $65.00 to $71.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. Stifel Nicolaus reduced their price objective on Revolution Medicines from $78.00 to $64.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Wedbush reaffirmed an "outperform" rating and issued a $67.00 price objective on shares of Revolution Medicines in a research note on Monday. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $59.00 price objective on shares of Revolution Medicines in a research note on Tuesday, April 8th. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Revolution Medicines presently has an average rating of "Buy" and a consensus price target of $66.67.

Revolution Medicines Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.